From USFDA
Natco Pharma announced that its marketing partner, Mylan Inc. has received a tentative approval for its Abbreviated New Drug Application for Sorafenib Tablets, 200 mg with the United States Food and Drug Administration. The product is the generic version of NEXAVAR, which is indicated for the treatment of certain types of cancers including unresectable hepatocellular carcinoma and advanced renal cell carcinoma.Powered by Capital Market - Live News
